|
|
| |
|||||
| Company (Symbol) | Type Of Financing | Number Of Shares, Units Or Warrants (M) | Amount Raised (M) |
||
| Aradigm Corp. (ARDM) | Private placement of Series A convertible preferred stock | 2S | $48.4 |
||
| Axonyx Inc. (AXYX) | Private placement of common stock and warrants | W for 0.98S | $6.4 |
||
| Bioject Medical Technologies Inc. (BJCT) | Private placement of common stock | 0.35S | $3.85 |
||
| Cephalon Inc. (CEPH) | Private placement of convertible notes | ND | $500 |
||
| Columbia Laboratories Inc. (AMEX:COB) | Private placement of common stock | 1.12S | $2.97 |
||
| ConjuChem Inc. (Canada; TSE:CJM) | Private placement of a convertible note | ND | C$30 (US$19) |
||
| Corixa Corp. (CRXA) | Equity line of credit | ND | $75 |
||
| Cubist Pharmaceuticals Inc. (CBST) | Private placement of convertible subordinated notes | ND | $40 |
||
| EntreMed Inc. (ENMD) | Private placement of common stock and warrants | 2.9S and W for 0.73S | $22.6 |
||
| Epimmune Inc. (EPMN) | Private placement of common stock | 2S | $5 |
||
| GenVec Inc. (GNVC) | Private placement of common stock | 3.6S | $13 |
||
| GlycoGenesys Inc. (GLGS) | Private placement of common stock | 4.2S | $5.3 |
||
| Heska Corp. (HSKA) | Private placement of common stock | 7.8S | $6 |
||
| Hollis-Eden Pharmaceuticals Inc. (HEPH) | Private placement of common stock and warrants | 1.3S and W for 0.13S | $11.5 |
||
| IGEN International Inc. (IGEN) | Private placement of common stock | 1.02S | $30 |
||
| Interneuron Pharmaceuticals Inc. (IPIC) | Private placement of common stock | 3.125S | $25 |
||
| Invitrogen Corp. (IVGN) | Private placement of convertible subordinated notes | ND | $500 |
||
| Martek Biosciences Corp. (MATK) | Private placement of common stock | 1.2S | $22.5 |
||
| Orphan Medical Inc. (ORPH) | Private placement of common stock | 1.7S | $14.1 |
||
| Senesco Technologies Inc. (OTC BB:SENO) | Private placement of common stock and warrants | 1.1S and W for 1S | $2 |
||
| Valentis Inc. (VLTS) | Private placement of common stock | 6.1S | $13.8 |
||
| Visible Genetics Inc. (VGIN) | Private placement of common stock | 2.6S | $22 |
||
| |
|||||
| Company (Symbol) | Type Of Financing | Number Of Shares, Units Or Warrants (M) | Amount Raised (M) |
||
| Advanced Tissue Sciences Inc. (ATIS) | Private placement of common stock | 3.53S | $14.7 |
||
| Alliance Pharmaceutical Corp. (ALLP) | Private placement of common stock and warrants | 4.3S and W for 4.3S | $15.1 |
||
| Ariad Pharmaceuticals Inc. (ARIA) | Private placement of common stock | 1.9S | $8 |
||
| Cel-Sci Corp. (AMEX:CVM) | Equity and debt financings | ND | $2.2 |
||
| Genetronics Biomedical Corp. (AMEX:GEB) | Private placement of special warrants | 5.2W | $2.3 |
||
| Genta Inc. (GNTA) | Private placement of common stock | 2.5S | $32.7 |
||
| Hercules Development Group (OTC BB:HDVG) | Private equity financing | ND | $3.2 |
||
| Neoprobe Corp. (OTC BB:NEOP) | Equity financing agreement | ND | $10 |
||
| MGI Pharma Inc. (MOGN) | Private placement of common stock | 0.9S | $11.8 |
||
| Ophidian Pharmaceuticals Inc. (OTC BB:OPHD) | Private placement of debentures convertible into shares | ND | $2 |
||
| Palatin Technologies Inc. (AMEX:PTN) | Private placement of common stock | 4.9S | $11 |
||
| Peregrine Pharmaceuticals Inc. (PPHM) | Private placement of common stock and warrants | 5.75S and W for 1.725S | $5.75 |
||
| Ribozyme Pharmaceuticals Inc. (RZYM) | Private placement of common stock and warrants | 2.3S and W for 0.23S | $9.5 |
||
| The Immune Response Corp. (IMNR) | Private placement of a convertible note and warrant | W for 1.73S | $2 |
||
| Sepracor Inc. (SEPR) | Private placement of convertible subordinated notes | ND | $500 |
||
| |
|||||
| Company (Symbol) | Type Of Financing | Number Of Shares, Units Or Warrants (M) | Amount Raised (M) |
||
| AlphaRx Inc. (Canada; OTC BB:AHRX) | Private placement of common stock and warrants | ND | $0.5 |
||
| AltaRex Corp. (OTC BB:ALXFF; TSE:AXO) | Private placement of special units | 7.2U | C$12.6 (US$8) |
||
| Avant Immunotherapeutics Inc. (AVAN) | Private placement of common stock | 3S | $14 |
||
| Biomira Inc. (BIOM) | Private placement of convertible debentures and warrants | W for 0.75S | $15 |
||
| Cubist Pharmaceuticals Inc. (CBST) | Private placement of subordinated notes | ND | $125 |
||
| Discovery Laboratories Inc. (DSCO) | Private placement of units and warrants | U for 3.5S and W for 0.7S | $7.7 |
||
| Essential Therapeutics Inc. (ETRX) | Private equity financing | ND | $60 |
||
| MGI Pharma Inc. (MOGN) | Private placement of common stock | 3S | $31 |
||
| Nastech Pharmaceutical Company Inc. (NSTK) | Private placement of common stock | 1.1S | $5.8 |
||
| Organogenesis Inc. (AMEX:ORG) | Private placement of convertible subordinated notes and common stock | 2.17S | $20.25 |
||
| Paradigm Genetics Inc. (PDGM) | Private placement of common stock | 5.1S | $28 |
||
| Regeneron Pharmaceuticals Inc. (REGN) | Private placement of seven-year convertible notes | ND | $200 |
||
| ReGen Therapeutics plc (UK; LSE:RGT) | Private placement of common stock | 10.5S | 1 (US$1.42) |
||
| Siga Technologies Inc. (SIGA) | Private placement of common stock and warrants | 0.67S and W for 0.33S | $2 |
||
| Triangle Pharmaceuticals Inc. (VIRS) | Private placement of common stock | 18.7S | $49.5 |
||
| |
|||||
| Company (Symbol) | Type Of Financing | Number Of Shares, Units Or Warrants (M) | Amount Raised (M) |
||
| Aastrom Biosciences Inc. (ASTM) | Private placement of common stock | 7.7S | $11 |
||
| Dragon Pharmaceuticals Inc. (Canada; OTC BB:DRUG) | Private placement of units | 3.5U | $7 |
||
| PPL Therapeutics plc (Scotland; LSE:PTH) | Private placement of common stock | ND | 30 (US$43.3) |
||
| Protalex Inc. (OTC BB:PRTX) | Private placement of common stock | ND | $1.1 |
||
| SIGA Technologies Inc. (SIGA) | Private placement of common stock and warrants | 0.4S and W for 0.3S | $1.16 |
||
| Synaptic Pharmaceutical Corp. (SNAP) | Private placement of convertible preferred stock | 5.4S | $31.6 |
||
| ViroLogic Inc. (VLGC) | Private placement of preferred stock and warrants | 3.2W | $9.6 |
||
| |
|||||
| Company (Symbol) | Type Of Financing | Number Of Shares, Units Or Warrants (M) | Amount Raised (M) |
||
| Antex Biologics Inc. (AMEX:ANX) | Private placement of convertible preferred stock and warrants | ND | $3 |
||
| Aphton Corp. (APHT) | Private placement of common stock | 1.2S | $14.25 |
||
| Aradigm Corp. (ARDM) | Private placement of common stock and warrants | 3.6S and 0.36W | $14.6 |
||
| BioTime Inc. (AMEX:BTX) | Private placement of 10% nonconvertible debentures and warrants | ND | $3.5 |
||
| Hyseq Inc. (HYSQ) | Private placement of common stock | 3.04S | $21.3 |
||
| Incara Pharmaceuticals Corp. (INCR) | Private placement of common stock and warrants | 4.25S and 1W | $7 |
||
| Ortec International Inc. (ORTC) | Financing involving non-equity capital | ND | $25 |
||
| Synaptic Pharmaceutical Corp. (SNAP) | Private placement of convertible preferred stock | 2.2S | $9.4 |
||
| Triangle Pharmaceuticals Inc. (VIRS) | Private placement of common stock | 9.62S | $25.51 |
||
| ViroLogic Inc. (VLGC) | Private placement of preferred stock and warrants | 3.2W | $9.55 |
||
| Viventia Biotech Inc. (Canada; TSE:VBI) | Private placement of units | 17.9U | C$6 (US$3.9) |
||
| |
|||||
| Company (Symbol) | Type Of Financing | Number Of Shares, Units Or Warrants (M) | Amount Raised (M) |
||
| Esperion Therapeutics Inc. (ESPR) | Private placement of common stock | 3.2S | $24 |
||
| Generex Biotechnology Corp. (Canada; GNBT) | Private placement of common stock and warrants | ND | US$11 |
||
| Genset SA (France; GENXY) | Equity financing agreement | ND | EUR50 (US$43.8) |
||
| ICN Pharmaceuticals Inc. (NYSE:ICN) | Private placement of common stock | ND | $525 |
||
| Isotechnika Inc. (Canada; TSE:ISA) | Private placement of warrants | 5.7W | C$25.08 (US$16.24) |
||
| LifeCell Corp. (LIFC) | Private placement of common stock | 3.125S and W to purchase 1.75S | $6 |
||
| MacroChem Corp. (MCHM) | Private placement of common stock | 1.56S | $10.1 |
||
| Matritech Inc. (NMPS) | Private placement of common stock | 0.33S | $1 |
||
| New unnamed firm formed by the merger of Microcide Pharmaceuticals Inc. (MCDE) and The Althexis Company Inc. | Private placement of redeemable preferred stock | ND | $60 |
||
| Penwest Pharmaceutical Co. (PPCO) | Private placement of common stock | 2.4S | $30 |
||
| Protein Polymer Technologies Inc. (OTC BB:PPTI) | Private placement of convertible preferred stock and warrants | ND | $1.2 |
||
| ViroLogic Inc. (VLGC) | Private placement of preferred stock and warrants | 3.2W | $6.7 |
||
| |
|||||
| Company (Symbol) | Type Of Financing | Number Of Shares, Units Or Warrants (M) | Amount Raised (M) |
||
| AtheroGenics Inc. (AGIX) | Private placement of common stock | 3.6S | $20.6 |
||
| Bioniche Life Sciences Inc. (Canada; TSE:BNC) | Private placement of special warrants | ND | C$10 (US$6.6) |
||
| Biopure Corp. (BPUR) | Equity line agreement | ND | $75 |
||
| BioTransplant Inc. (BTRN) | Private placement of common stock | 3S | $19 |
||
| Cellegy Pharmaceuticals Inc. (CLGY) | Private placement of common stock | 2.7S | $15.4 |
||
| Cell Therapeutics Inc. (CTIC) | Private placement of convertible subordinated notes | ND | $175 |
||
| COR Therapeutics Inc. (CORR) | Private placement of convertible senior notes | ND | $300 |
||
| Cytogen Corp. (CYTO) | Private placement of common stock | 1.82S | $8.19 |
||
| DepoMed Inc. (AMEX:DMI) | Private placement of shares and warrants | 2.9S and 1.5W | $12.3 |
||
| DNAPrint genomics Inc. (OTC BB:DNAP) | Growth capital funding | ND | $2 |
||
| Enzon Inc. (ENZN) | Private placement of convertible subordinated notes | ND | $400 |
||
| Gliatech Inc. (GLIA) | Equity financing agreement | ND | $2.5 |
||
| Guilford Pharmaceuticals Inc. (GLFD) | Private placement of common stock | 3S | $59 |
||
| InKine Pharmaceutical Co. (INKP) | Private placement of convertible subordinated notes | ND | $10 |
||
| Matritech Inc. (NMPS) | Private placement of common stock | 0.331S | $1.08 |
||
| Orchid BioSciences Inc. (ORCH) | Private placement of common stock | 5.95S | $35.7 |
||
| Ortec International Inc. (ORTC) | Non-equity funding based on milestones | ND | $25 |
||
| Procyon BioPharma Inc. (Canada; TSE:PBP) | Private placement of common stock | ND | C$1 (US$0.66) |
||
| SangStat Inc. (SANG) | Private placement of common stock | 1.36S | $15 |
||
| Sonus Pharmaceuticals Inc. (SNUS) | Private placement of common stock | 1.7S | $4.9 |
||
| Theratechnologies Inc. (Canada; TSE:TH) | Private placement of common stock | ND | C$60 (US$39.41) |
||
| |
|||||
| Company (Symbol) | Type Of Financing | Number Of Shares, Units Or Warrants (M) | Amount Raised (M) |
||
| Adolor Corp. | Private placement of newly issued stock | 3S | $60 |
||
| AltaRex Corp. (Canada; TSE:AXO; OTC BB:ALXFF) | Private placement of special warrants | ND | C$8.4 (US$5.4) |
||
| Amylin Pharmaceuticals Inc. (AMLN) | Private placement of common stock | 3.5S | $35 |
||
| Bioject Medical Technologies Inc. (BJCT) | Equity financing agreement | 1.5S (plus warrants to purchase 0.225S) | $15 |
||
| BioMarin Pharmaceutical Inc. (BMRN) | Private placement of common stock and warrants | 4.8S (plus warrants for another 0.7S) | $45 |
||
| Cephalon Inc. (CEPH) | Private placement of convertible subordinated notes | ND | $400 |
||
| Cerus Corp. (CERS) | Private placement of common stock | 1.5S | $78 |
||
| Genzyme Corp. (GENZ) | Private placement of convertible subordinated notes | ND | $500 |
||
| Lynx Therapeutics Inc. (LYNX) | Private placement of newly issued stock | 1.7S | $11.1 |
||
| Medicure Inc. (Canada; CDNX:MPH) | Private placement of units | 2.6U | C$2.6 (US$1.7) |
||
| MGI Pharma Inc. (MOGN) | Private placement of common stock | 4S | $29.2 |
||
| Mindsense Biosystems Ltd. (Israel) | Equity financing agreement | ND | $2 |
||
| NeoTherapeutics Inc. (NEOT) | Private placement of common stock | 1.4S | $6 |
||
| Organogenesis Inc. (AMEX:ORG) | Private placement of common stock | 1.9S | $15.4 |
||
| Phage Therapeutics International Inc. (OTC BB:PTXX) | Private placement of convertible stock | 2.1U | $1.5 |
||
| StemCells Inc. (STEM) | 30-month equity financing | ND | $30 |
||
| Synsorb Biotech Inc. (Canada; TSE:SYB; SYBB) | Equity line of financing | up to 1S | ND |
||
| Transgene (France; TRGNY) | Rights offering of common stock | 4.21S | EUR63.1 (US$54) |
||
| VaxGen Inc. (VXGN) | Private placement of convertible preferred stock | 0.02S | $20 |
||
| Viventia Biotech Inc. (Canada; TSE:VBI) | Equity financing agreement | ND | C$6 (US$3.9) |
||
| The Medicines Company Inc. (MDCO) | Private placement of common stock | 4S | $41.8 |
||
| Trimeris Inc. (TRMS) | Private placement of common stock | 1.4S | $43.4 |
||
| |
|||||
| Company (Symbol) | Type Of Financing | Number Of Shares, Units Or Warrants (M) | Amount Raised (M) |
||
| Bioniche Life Sciences Inc. (Canada; TSE:BNC) | Financing from the Canadian government | ND | C$17.2 (US$10.99) |
||
| Cel-Sci Corp. (AMEX:CVM) | Equity financing agreement | ND | $10 |
||
| DepoMed Inc. (AMEX:DMI) | Draw down financing over nine-month period | ND | $2 |
||
| Cytomedix Inc. (OTC BB:CYDX) | Equity financing agreement | ND | $14.7 |
||
| Gliatech Inc. (GLIA) | Equity financing agreement | ND | $5 |
||
| International Wex Technologies Inc. (Canada; CDNX:WXI) | Private placement of common stock | 0.3 | $0.64 |
||
| Transgene SA (France; TRGNY) | Rights offering for new shares to existing holders | 5.31 | EUR79.72 (US$71.53) |
||
| |
|||||
| Company (Symbol) | Type Of Financing | Number Of Shares, Units Or Warrants (M) | Amount Raised (M) |
||
| Antares Pharma (MEDJ) | Private placement of common stock | 0.5S | $3 |
||
| Atlantic Technology Ventures Inc. (ATLC) | Common stock purchase agreement | ND | $6 |
||
| Axys Pharmaceuticals Inc. (AXPH) | Exercise of options to acquire common stock | 2.4S | ND |
||
| CollaGenex Pharmaceuticals Inc. (CGPI) | Private placement of common stock | 1.5S | $7.5 |
||
| Helix BioPharma Corp. (Canada; TSE:HBP) | Exercise of Series A warrants | 1.23W | C$3.93 (US$2.56) |
||
| IGEN International Inc. (IGEN) | Private placement of common stock | 0.79 shares | $9.5 |
||
| Martek Biosciences Corp. (MATK) | Private placement of common stock | 1.28S (plus warrants to purchase 0.3S) | $20 |
||
| MGI Pharma Inc. (MOGN) | Flexible underwritten equity facility | 0.1S | $100 |
||
| Nastech Pharmaceutical Co. Inc. (NSTK) | Private placement of common stock | 0.86S | $4.2 |
||
| NeoTherapeutics Inc. (NEOT) | Private placement of common stock and warrants | 1.25S and 0.125W | $5 |
||
| Oxford BioMedica plc (UK; LSE:OXB) | Private placement of common stock | 59.2S | 32.6 (US$46.176) |
||
| Triangle Pharmaceuticals Inc. (VIRS) | Private placement of Series B preferred stock | 0.2S | $12 |
||
| V.I. Technologies Inc. (VITX) | Private placement of common stock | 1.6S | $10 |
||
| |
|||||
| Company (Symbol) | Type Of Financing | Number Of Shares, Units Or Warrants (M) | Amount Raised (M) |
||
| Advanced Viral Research Corp. (OTC BB:ADVR) | Credit line financing | ND | $50 |
||
| Antares Pharma (MEDJ) | Private placement of common stock | 1.2S (plus warrants to purchase 0.3S) | $7 |
||
| BioMarin Pharmaceutical Inc. (BMRN) | Equity financing | ND | $50 |
||
| BioPulse International Inc. (OTC BB:BIOP) | Bridge financing | ND | $3 |
||
| Columbia Laboratories Inc. (AMEX:COB) | Equity financing | ND | $20 |
||
| Heska Corp. (HSKA) | Private placement of common stock | 4.57S | $5.7 |
||
| Igen International Inc. (IGEN) | Equity financing facility | ND | $60 |
||
| La Jolla Pharmaceutical Co. (LJPC) | Private placement of common stock | 5.7S | $35.3 |
||
| NeoTherapeutics Inc. (NEOT) | Private placement of common stock | 1.6S | $3.5 |
||
| Pheromone Sciences Corp. (Canada; CDNX:PHS) | Private placement of special warrants | 2W | C$2 (US$1.31) |
||
| Samaritan Pharmaceuticals (OTC BB:SPHC) | Equity financing | ND | $20 |
||
| |
|||||
| Company (Symbol) | Type Of Financing | Number Of Shares, Units Or Warrants (M) | Amount Raised (M) |
||
| Acacia Research Corp. (ACRI) | Private placement of common stock | 1.1S | $19 |
||
| Aradigm Corp. (ARDM) | Exercise of a put option | 0.34S | $5 |
||
| Aviron Inc. (AVIR) | Private placement of common stock | 0.161S | $8 |
||
| Corixa Corp. (CRXA; now merged with Coulter Pharmaceuticals Inc.) | Draw down of equity line | 37.5S | $37.5 |
||
| Gene-Cell Inc. (OTC BB:GCLL) | Private placement of common stock | 1.875S | $1.5 |
||
| ImClone Systems Inc. (IMCL) | Redemption of Series A preferred stock | ND | $24 |
||
| Interleukin Genetics Inc. (ILGN) | Private placement of common stock and warrants | 1.2S; 0.6W | $3 |
||
| Ligand Pharmaceuticals Inc. (LGND) | Draw down of zero-convertible notes | ND | $10 |
||
| Ligand Pharmaceuticals Inc. (LGND) | Private placement of common stock | 2S | $24 |
||
| Nexell Therapeutics Inc. (NEXL) | Private placement of common stock | ND | $25 |
||
| Prana Biotechnology Ltd. (Australia; ASX:PBT) | Private placement of common stock | 6.66S | A$5 (US$2.8) |
||
| SafeScience Inc. (SAFS) | Private placement of common stock and warrants | 3.96S (plus warrants for another 1.964S) | $4.7 |
||
| SangStat Medical Corp. (SANG) | Private placement of common shares | 1.3S | $12.5 |
||
| Texas Biotechnology Corp. (AMEX:TXB) | Exercise of warrants | 2.57W | $21.7 |
||
| Triangle Pharmaceuticals Inc. (VIRS) | Private placement of common stock | 7.7S | $46.2 |
||
| |
||||||
| Company | Location | Date | Amount Raised (M) | Round |
||
| Agilix Corp. | New Haven, Conn. | 12/18 | $21 | Second |
||
| Altus Inc. | Cambridge, Mass. | 12/27 | $15 | Second |
||
| Amnis Corp. | Seattle | 12/3 | $8.75 | Second |
||
| Astex Technology Ltd. | Cambridge, UK | 12/17 | $8.1 | ND |
||
| Avalon Pharmaceuticals Inc. | Gaithersburg, Md. | 12/17 | $70 | Second |
||
| A-Viral A/S | Oslo, Norway | 12/19 | NOK15 (US$1.7) | ND |
||
| Calyx Therapeutics Inc. | Hayward, Calif. | 12/5 | $30 | Fourth |
||
| Cytochroma Inc. | Kingston, Ontario | 12/18 | $2.3 | Second |
||
| ExonHit Therapeutics SA | Paris | 12/3 | EUR30 (US$26.7) | Third |
||
| Genome Express | Grenoble, France | 12/10 | EUR12.4 (US$11.02) | Second |
||
| Guava Technologies Inc. | Burlingame, Calif. | 12/20 | $6 | Fourth |
||
| Infigen Inc. | Deforest, Wis. | 12/19 | ND | First |
||
| Micromet AG | Martinsried, Germany | 12/26 | EUR6 (US$5.3) | Fourth |
||
| Mindset BioPharmaceuticals Inc. | Jerusalem | 12/20 | $15 | ND |
||
| MitoKor | San Diego | 12/21 | $25 | ND |
||
| Myogen Inc. | Denver | 12/31 | $14 | Fourth |
||
| Novocell Inc. | Irvine, Calif. | 12/19 | ND | Third |
||
| Performance Plants Inc. | Kingston, Ontario | 12/21 | $2.7 | ND |
||
| Pharmacore AB | Uppsala, Sweden | 12/26 | SEK45 (US$4.5) | ND |
||
| Pharmion Corp. | Boulder, Colo. | 12/3 | $65 | ND |
||
| Phylogix Inc. | Scarborough, Maine | 12/7 | $2.95 | First |
||
| Synaptica Ltd. | Oxford, UK | 12/17 | $5.1 | ND |
||
| Syrrx Inc. | San Diego | 12/26 | $18.5 | ND |
||
| Trellis Bioscience Inc. | San Francisco | 12/3 | ND | First |
||
| Xantos Biomedicine GmbH | Bornheim, Germany | 12/26 | EUR21 (US$18.7) | Second |
||
| |
||||||
| Company | Location | Date | Amount Raised (M) | Round |
||
| Aegis Analytical Corp. | Lafayette, Colo. | 11/19 | $14.5 | Second |
||
| Ambit Biosciences Corp. | San Diego | 11/7 | $10 | Second |
||
| Auxilium Inc. | East Norriton, Pa. | 11/8 | $28 | Second |
||
| Bioheart Inc. | Fort Lauderdale, Fla. | 11/20 | $5 | ND |
||
| Fludigm Corp. | South San Francisco | 11/12 | $34 | Third |
||
| Glycominds Ltd. | Maccabim, Israel | 11/6 | $7.1 | ND |
||
| Jerini AG | Berlin | 11/13 | EUR20 (US$17.6) | Second |
||
| Locus Discovery Inc. | Blue Bell, Pa. | 11/7 | $12 | Third |
||
| Lorantis Ltd. | Cambridge, UK | 11/6 | 4.7 (US$7) | Second |
||
| MorphoGen Pharmaceuticals Inc. | San Diego | 11/19 | $8.5 | Third |
||
| NuGEN Technologies Inc. | San Carlos, Calif. | 11/30 | $10.8 | Second |
||
| Protein Sciences Corp. | Meriden, Conn. | 11/12 | $2 | ND |
||
| Rinat Neuroscience Corp. | Palo Alto, Calif. | 11/6 | $17.5 | First |
||
| Scion Pharmaceuticals Inc. | San Mateo, Calif. | 11/6 | $4 | First |
||
| |
||||||
| Company | Location | Date | Amount Raised (M) | Round |
||
| Affibody AB | Stockholm, Sweden | 10/3 | $28 | ND |
||
| Altus Inc. | Cambridge, Mass. | 10/3 | $35 | ND |
||
| Angiogene Inc. | Montreal | 10/11 | C12 (US$7.7) | ND |
||
| Ardana Bioscience Ltd. | Edinburgh, Scotland | 10/31 | 13.3 (US$20) | First |
||
| Atto BioScience Inc. | Rockville, Md. | 10/29 | $3 | First |
||
| Axxima Pharmaceuticals AG | Martinsried, Germany | 10/22 | $27.3 | ND |
||
| Capsulation NanoScience AG | Berlin, Germany | 10/3 | DM6 (US$2.8) | First |
||
| Cetek Corp. | Marlborough, Mass. | 10/11 | $14 | ND |
||
| Chroma Therapeutics Ltd. | Oxford, UK | 10/25 | 1.5 (US$2.15) | Seed |
||
| Cyternex Inc. | San Diego | 10/17 | $3.55 | First |
||
| Cytochroma Inc. | Kingston, Ontario | 10/29 | C$12 (US$7.6) | ND |
||
| Discovery Therapeutics Inc. | Richmond, Va. | 10/9 | $45 | Fourth |
||
| DOV Pharmaceutical Inc. | Hackensack, N.J. | 10/17 | $10.4 | Fourth |
||
| D-Pharm Ltd. | Rehovot, Israel | 10/16 | $30 | Fourth |
||
| ESBATech AG | Zurich, Switzerland | 10/30 | ND | Second |
||
| Galileo Genomics Inc. | Montreal | 10/10 | C$16.5 (US$10.5) | ND |
||
| GeneFormatics Inc. | San Diego | 10/17 | $22 | Third |
||
| International Therapeutics Inc. | Seattle | 10/4 | $2 | Second |
||
| Interomex BioPharmaceuticals Inc. | Vancouver, British Columbia | 10/3 | C$6.3 (US$4) | Second |
||
| Intronn Inc. | Raleigh, N.C. | 10/15 | $7 | First |
||
| Metabasis Therapeutics Inc. | San Diego | 10/23 | $19.2 | Fourth |
||
| NimbleGen Systems Inc. | Madison, Wis. | 10/17 | $1.5 | Second |
||
| Novocell Inc. | Irvine, Calif. | 10/3 | $7 | Second |
||
| Protedyne | Windsor, Conn. | 10/12 | $12 | ND |
||
| RiboTargets Ltd. | Cambridge, Mass. | 10/3 | 32 (US$47) | Third |
||
| Sagres Discovery Inc. | Davis, Calif. | 10/5 | $20 | Second |
||
| Sosei Co. Ltd. | Tokyo | 10/22 | $6.5 | Second |
||
| Switch Biotech AG | Martinsried, Germany | 10/11 | EUR18 (US$16.5) | Third |
||
| Therion Biologics Corp. | Cambridge, Mass. | 10/30 | $36.5 | Third |
||
| ToleRx | Cambridge, Mass. | 10/23 | $17 | Second |
||
| ViaCell Inc. | Boston | 10/31 | $15 | ND |
||
| |
||||||
| Company | Location | Date | Amount Raised (M) | Round |
||
| Amphora Discovery Corp. | Research Triangle Park, N.C. | 9/27 | $11 | First |
||
| Athenix Corp. | Research Triangle Park, N.C. | 9/10 | $8 | First |
||
| Bio Information Technologies Ltd. | Rama Gan, Israel | 9/10 | $7.8 | First |
||
| Cellfactors plc | Cambridge, UK | 9/19 | 2.5 (US$3.66) | ND |
||
| Cumbre Inc. | Dallas | 9/20 | $26 | Second |
||
| Entelos Inc. | Menlo Park, Calif. | 9/6 | $25 | ND |
||
| EuroProteome AG | Hennigsdorf, Germany | 9/26 | EUR9.5 (US$8.77) | Second |
||
| Locus Discovery Inc. | Blue Bell, Pa. | 9/7 | $28 | Third |
||
| MacroGenics Inc. | Seattle | 9/25 | $13.5 | First |
||
| Merix Bioscience Inc. | Durham, N.C. | 9/10 | $39.5 | Second |
||
| NimbleGen Systems Inc. | Madison, Wis. | 9/11 | $9 | ND |
||
| Protiva Biotherapeutics Inc. | Vancouver, British Columbia | 9/6 | C$14.5 (US$9.3) | ND |
||
| PTC Therapeutics Inc. | South Plainfield, N.J. | 9/20 | $40 | Second |
||
| Solexa Ltd. | Cambridge, UK | 9/24 | US$17 | ND |
||
| SynGenix Ltd. | Cambridge, UK | 9/13 | 5 (US$7.25) | ND |
||
| |
||||||
| Company | Location | Date | Amount Raised (M) | Round |
||
| AM Pharma BV | Bilthoven, the Netherlands | 8/15 | EUR0.64 (US$0.59) | First |
||
| Ark Therapeutics Ltd. | London | 8/29 | 14.5 (US$21) | Third |
||
| Automated Cell Inc. | Pittsburgh | 8/6 | $2.6 | ND |
||
| Chimeric Therapies Inc. | Laguna Niguel, Calif. | 8/8 | $9.7 | ND |
||
| Eyetech Pharmaceuticals Inc. | New York | 8/9 | $108.5 | Third |
||
| Ionix Pharmaceuticals Ltd. | London | 8/8 | 8 (US$11.4) | First |
||
| LaunchCyte LLC | Pittsburgh | 8/8 | $0.7 | ND |
||
| MBT Munich Biotechnology GmbH | Munich, Germany | 8/21 | EUR30.3 (US$27.8) | Second |
||
| Morphotek Inc. | Philadelphia | 8/13 | $10 | Second |
||
| Myogen Inc. | Denver | 8/27 | $52.4 | Fourth |
||
| Q3DM Inc. | San Diego | 8/22 | $1.5 | First |
||
| TaiGen Biotechnology Co. | Taipei, Taiwan | 8/20 | $48 | First |
||
| |
||||||
| Company | Location | Date | Amount Raised (M) | Round |
||
| ActivX Biosciences Inc. | La Jolla, Calif. | 7/10 | $20 | First |
||
| Adaptive Screening Ltd. | London | 7/25 | 0.5 (US$0.71) | Seed |
||
| Affymax Inc. | Palo Alto, Calif. | 7/30 | $51 | First |
||
| BioVex Ltd. | London | 7/30 | 10 (US$14.2) | ND |
||
| Cognetix Inc. | Salt Lake City | 7/31 | $17 | Second |
||
| Critical Therapeutics Inc. | Cambridge, Mass. | 7/17 | $10 | First |
||
| De Novo Pharmaceuticals Ltd. | Cambridge, UK | 7/26 | 16.75 (US$23.93) | Second |
||
| EluSys Therapeutics Inc. | Pine Brook, N.J. | 7/17 | $17 | Third |
||
| Endocyte Inc. | West Lafayette, Ind. | 7/16 | $7.6 | First |
||
| Inpharmatica | London | 7/3 | 31.3 (US$44) | Second |
||
| Integrative Proteomics Inc. | Toronto | 7/31 | $25 | Second |
||
| Ipsogen | Marseille, France | 7/18 | EUR4.5 (US$3.9) | Second |
||
| MetaProbe LLC | San Diego | 7/5 | $5 | First |
||
| MetriGenix Inc. | Gaithersburg, Md. | 7/19 | $15 | First |
||
| Morphochem AG | Munich, Germany | 7/19 | EUR15 (US$13) | Fourth |
||
| Nereus Pharmaceuticals Inc. | San Diego | 7/30 | $23.6 | Second |
||
| NewBiotics Inc. | San Diego | 7/26 | $11 | Third |
||
| Prolinx Inc. | Bothell, Wash. | 7/17 | $16.8 | Fifth |
||
| Signature BioScience Inc. | Hayward, Calif. | 7/9 | $43 | Fourth |
||
| Trophos | Marseille, France | 7/31 | EUR5 (US$4.4) | First |
||
| |
||||||
| Company | Location | Date | Amount Raised (M) | Round |
||
| Amaxa GmbH | Cologne, Germany | 6/13 | EUR13 (US$11.6) | Second |
||
| Amedis Pharmaceuticals Ltd. | Royston, UK | 6/13 | 4 (US$5.56) | ND |
||
| Biophage Inc. | Montreal | 6/20 | C$2.6 (US$1.7) | ND |
||
| Biophage Inc. | Montreal | 6/27 | C$0.85 (US$0.56) | ND |
||
| Biovitrum AB | Stockholm, Sweden | 6/11 | $130 | Seed |
||
| Corcept Therapeutics Inc. | Menlo Park, Calif. | 6/20 | $37 | Third |
||
| Corus Pharma Inc. | Seattle | 6/6 | $18.5 | First |
||
| Cyclacel Ltd. | Dundee, UK | 6/14 | 34 (US$47.6) | Third |
||
| Genicon Sciences Corp. | San Diego | 6/6 | $32 | Fourth |
||
| Guava Technologies Inc. | Burlingame, Calif. | 6/21 | $17.5 | Second |
||
| Ichor Corp. | Lyon, France | 6/18 | $2 | ND |
||
| IntegraGen | Evry, France | 6/21 | EUR6.3 (US$5.4) | First |
||
| Kourion Therapeutics | Dusseldorf, Germany | 6/28 | EUR12 (US$10.3) | ND |
||
| Medgenics Inc. | Misgav, Israel | 6/20 | $7 | First |
||
| Neurogenetics Inc. | San Diego | 6/25 | $9 | Second |
||
| NeuroSearch A/S | Ballerup, Denmark | 6/21 | DKK128.6 (US$14.7) | ND |
||
| NitroMed Inc. | Bedford, Mass. | 6/14 | $31.4 | ND |
||
| Screentec BV | Leiden, the Netherlands | 6/13 | EUR6.5 (US$5.54) | First |
||
| Sterix Ltd. | Oxford, UK | 6/20 | 8 (US$11.1) | ND |
||
| VitaGen Inc. | La Jolla, Calif. | 6/28 | $14 | Third |
||
| |
||||||
| Company | Location | Date | Amount Raised (M) | Round |
||
| AGY Therapeutics Inc. | South San Francisco | 5/7 | $13 | Second |
||
| Aptus Genomics Inc. | Rockville, Md. | 5/14 | $6.2 | First |
||
| Astex Technology Ltd. | Cambridge, UK | 5/4 | 22.7 (US$32.5) | First |
||
| BioMimetic Pharmaceuticals Inc. | Nashville, Tenn. | 5/24 | $6.5 | ND |
||
| Conforma Therapeutics Corp. | San Diego | 5/9 | $15 | First |
||
| Corgentech Inc. | South San Francisco | 5/3 | $13 | Second |
||
| Gemin X Biotechnologies Inc. | Montreal | 5/3 | $12.6 | Second |
||
| Genicon Science Corp. | San Diego | 5/2 | $27 | Third |
||
| Isogenica Ltd. | Cambridge, UK | 5/16 | US$3 | Seed |
||
| Memorec Stoffel GmbH | Cologne, Germany | 5/16 | EUR12.8 (US$11.3) | ND |
||
| Molecular Mining Corp. | Kingston, Ontario | 5/23 | US$8 | Second |
||
| Molecular Reflections Inc. | San Diego | 5/7 | $14.2 | Second |
||
| Neurotech SA | Evry, France | 5/29 | EUR35 (US$30) | Third |
||
| Novirio Pharmaceuticals Ltd. | Cambridge, Mass. | 5/7 | $44 | Third |
||
| Point Therapeutics Inc. | Boston | 5/31 | $5.4 | Second |
||
| Rejuvenon Corp. | Houston | 5/2 | $12 | ND |
||
| Remedyne Corp. | Goleta, Calif. | 5/30 | $3.2 | First |
||
| Strakan Group Ltd. | Galashiels, Scotland | 5/8 | 30.5 (US$43.5) | ND |
||
| ThromboGenics Ltd. | Dublin, Ireland | 5/10 | $12.8 | ND |
||
| Xenon Genetics Inc. | Vancouver, British Columbia | 5/4 | $2.6 | Second |
||
| |
||||||
| Company | Location | Date | Amount Raised (M) | Round |
||
| Vectura Ltd. | Bath, England | 4/30 | 10.55 (US$15.09) | ND |
||
| Active Pass Pharmaceuticals Inc. | Vancouver, British Columbia | 4/30 | C$7.7 (US$5.01) | ND |
||
| Ardana Bioscience Ltd. | Edinburgh, Scotland | 4/17 | 2 (US$2.87) | ND |
||
| Cellular Genomics Inc. | Branford, Conn. | 4/5 | $22 | Second |
||
| De Novo Pharmaceuticals Ltd. | Cambridge, UK | 4/4 | 950,000 (US$1.36) | Second |
||
| DeveloGen AG | Gottingen, Germany | 4/18 | EUR40 (US$39.9) | ND |
||
| DrugAbuse Sciences Inc. | Los Altos, Calif., and Paris | 4/5 | $24 | ND |
||
| Epicyte Pharmaceutical Inc. | San Diego | 4/16 | $16 | Fourth |
||
| Genteric Inc. | Alameda, Calif. | 4/26 | $22 | Second |
||
| Graffinity Pharmaceutical Design | Heidelberg, Germany | 4/18 | EUR30.6 (US$26.72) | ND |
||
| LifeSpan BioSciences Inc. | Seattle | 4/16 | $19 | Third |
||
| Lorantis Ltd. | London | 4/20 | 11.5 (US$16.5) | Second |
||
| Micromet AG | Martinsried, Germany | 4/4 | EUR40 (US$35.2) | Fourth |
||
| Novazyme Pharmaceuticals Inc. | Oklahoma City | 4/18 | $16 | Second |
||
| Perlegen Sciences Inc. | Santa Clara, Calif. | 4/3 | $100 | Second |
||
| Protein Polymer Technologies Inc. | San Diego | 4/2 | $1.9 | Seventh |
||
| U.S. Genomics Inc. | Woburn, Mass. | 4/4 | $17 | Second |
||
| Xenon Genetics Inc. | Vancouver, British Columbia | 4/4 | $45 | ND |
||
| |
||||||
| Company | Location | Date | Amount Raised (M) | Round |
||
| Acorda Therapeutics Inc. | Hawthorne, N.Y. | 3/9 | $6 | Ninth |
||
| Alchemia Inc. | Redwood City, Calif. | 3/29 | $8.2 | ND |
||
| Ardais Corp. | Lexington, Mass. | 3/19 | $33.5 | ND |
||
| CancerVax Corp. | Santa Monica, Calif. | 3/6 | $30 | First |
||
| Caprion Pharmaceuticals Inc. | Montreal | 3/13 | C$6.2 (US$4.1) | Second |
||
| Cellzome GmbH | Heidelberg, Germany | 3/1 | $31 | Second |
||
| Chromagen Inc. | San Diego | 3/23 | $15 | Sixth |
||
| Icagen Inc. | Research Triangle Park, N.C. | 3/27 | $22.8 | ND |
||
| LumiCyte Inc. | Fremont, Calif. | 3/30 | $20 | Second |
||
| Matrix Therapeutics Ltd. | Nottingham, UK | 3/19 | 2 (US$2.85) | First |
||
| NatImmune A/S | Copenhagen, Denmark | 3/22 | $7.5 | Second |
||
| NeuroMed Technologies Inc. | Vancouver, British Columbia | 3/27 | C$3.8 (US$2.4) | Second |
||
| Oasis Biosciences Inc. | San Diego | 3/29 | $7 | First |
||
| Pharmagenesis Inc. | Palo Alto, Calif. | 3/6 | ND | ND |
||
| Pharmasset Ltd. | Bridgetown, Barbados | 3/14 | $7.4 | ND |
||
| ProdiGene Inc. | College Station, Texas | 3/13 | $9 | ND |
||
| Santarus Inc. | San Diego | 3/8 | $33.2 | Third |
||
| SpiroGen Ltd. | Bryde, Isle of Wight, UK | 3/15 | 1 (US$1.4) | ND |
||
| Synt:em | Paris | 3/7 | EUR22 (US$20.43) | ND |
||
| |
||||||
| Company | Location | Date | Amount Raised (M) | Round |
||
| Bioheart Inc. | Fort Lauderdale, Fla. | 2/28 | $11 | First |
||
| Curacyte AG | Munich, Germany | 2/8 | EUR7 (US$6.5) | First |
||
| Quorex Pharmaceuticals Inc. | Carlsbad, Calif. | 2/27 | $18.5 | Second |
||
| Replicor Inc. | Montreal | 2/2 | C$2.6 (US$1.73) | ND |
||
| Zeptosens AG | Witterswil, Switzerland | 2/27 | CHF14 (US$8.3) | Second |
||
| |
||||||
| Company | Location | Date | Amount Raised (M) | Round |
||
| Advancis Pharmaceutical Corp. | Gaithersburg, Md. | 11/16 | $15 | Fourth |
||
| Acorda Therapeutics Inc. | Hawthorne, N.Y. | 1/9 | $33.7 | Ninth |
||
| BioMicro Systems Inc. | Salt Lake City | 1/17 | $1.5 | First |
||
| Cambridge Drug Discovery Ltd. | Cambridge, UK | 1/11 | 7.5 (US$11.26) | ND |
||
| EmerGen Inc. | Salt Lake City | 1/5 | $15 | First |
||
| EpiCept Corp. | Englewood Cliffs, N.J. | 1/12 | $13.4 | Third |
||
| Helicon Therapeutics Inc. | Uniondale, N.Y. | 1/10 | $6 | Second |
||
| IDgene Pharmaceuticals Ltd. | Jerusalem | 1/31 | $7.65 | Second |
||
| InfiMed Therapeutics Inc. | Cambridge, Mass. | 1/22 | $15 | Second |
||
| Intercell Biomedical Research & Development AG | Vienna, Austria | 1/16 | EUR27 (US$25.4) | Second |
||
| NeoGenesis Inc. | Cambridge, Mass. | 1/8 | $23 | Fourth |
||
| NeuroMed Technologies Inc. | Vancouver, British Columbia | 1/24 | C$17 (US$11.23) | Second |
||
| Oxxon Pharmaccines Ltd. | Oxford, UK | 1/2 | 4.7 (US$7.15) | ND |
||
| Panacos Pharmaceuticals Inc. | Gaithersburg, Md. | 1/18 | $3 | Second |
||
| Phylos Inc. | Lexington, Mass. | 1/4 | $25.1 | ND |
||
| Protiva Biotherapeutics Inc. | Vancouver, British Columbia | 1/24 | C$1.5 (US$1) | First |
||
| Raven Biotechnologies Inc. | San Carlos, Calif. | 1/9 | $20.6 | Second |
||
| Syrrx Inc. | San Diego | 1/8 | $54 | Second |
||
| Triad Therapeutics Inc. | San Diego | 1/4 | $30 | Second |
||